A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-15. Anything still debated is marked as such rather than presented as settled.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
He also portrayed Lucius Fox in Christopher Nolan's Dark Knight trilogy (2005–2012) and acted in the action films Wanted (2008), Red (2010), Oblivion (2013), the Now You See Me films (2013–2025), and Lucy (2014). Known for his distinctive voice, he has narrated numerous documentaries including The Long Way Home (1997), March of the Penguins (2005), Through the Wormhole (2010–2017), The Story of God with Morgan Freeman (2016–2019), Our Universe (2022) and Life on Our Planet (2023). He made his directorial debut with the drama Bopha! (1993). He founded the film production company Revelations Entertainment with business partner Lori McCreary in 1996, under which they produced projects such as the CBS political drama Madam Secretary (2014–2019).
Although previous studies proposed that Komodo dragon saliva contains a variety of highly septic bacteria that would help to bring down prey, research in 2013 suggested that the bacteria in the mouths of Komodo dragons are ordinary and similar to those found in other carnivores. Komodo dragons have good mouth hygiene. To quote Bryan Fry: "After they are done feeding, they will spend 10 to 15 minutes lip-licking and rubbing their head in the leaves to clean their mouth ... Unlike people have been led to believe, they do not have chunks of rotting flesh from their meals on their teeth, cultivating bacteria." They do have a slashing bite, which normally includes a dose of their neurotoxic venom and anticoagulant saliva. Komodo dragons do not wait for prey to die and track it at a distance, as vipers do; observations of them hunting deer, boar and in some cases buffalo reveal that they kill prey in less than half an hour during successful hunts, and usually in a matter of a few minutes, similar to large mammalian carnivores. The observation of prey dying of sepsis is instead likely based on misinterpretations of failed predation attempts caused by the natural instinct of water buffalo, which are not native to the islands where the Komodo dragon lives, to run into water after escaping an attack. The warm, faeces-filled water would then cause the infections. The study used samples from 16 captive dragons (10 adults and six neonates) from three US zoos.
One of the largest traditional markets in Taiwan, the Jianguo Market in Taichung, was torn down and replaced by a new facility in 2016. The new facilities provided better hygiene, disability accessibility, and refrigeration, but the relocation was initially met with hesitation from the local vendors before a grassroots outreach campaign led to greater acceptance.
=== Juice content === The juice content of the plant varies depending on the age of the plant, since younger plants contain more juice than older ones. The plant provides the least juice after seed maturation because the leaves have already begun decay at that point. Depending on the kind of press used, the amount of resulting juice varies significantly. On average, 50% of the weight of the plant is obtained as juice. The water to dry matter ratio of the juice shows high dry matter content in the upper part of the plant, and is lowest in the leaves when the seeds are ripe. The dry matter content is medium in the fibers and lowest in the shives. The relatively high content of dry matter implies a high percentage of substance components such as carbohydrates, amino acids, protein, fat, cannabinoids, polyphenols, as well as other substrates.
== Other constituents required for uptake == The components of the H. influenzae pathway necessary for NAD+, NMN, and NR uptake have been determined. Merdanovic et al. characterized two enzymes, an outer membrane nucleotide phosphatase, and an NAD+ nucleotidase (NadN) located in the periplasm. They showed that NAD+ and NMN cross the outer membrane mainly via the OmpP2 porin. Only NR can be utilized by the PnuC transport system located in the inner membrane. The pnuC gene product is the protein that is responsible for the main flow of the NR substrate into the cytoplasm. The study of Merdanovic et al. suggests that the RNK activity of NadR determines NR transport and is negatively regulated by cytoplasmic NAD+ feedback inhibition. Therefore, NR uptake is under NadR feedback control. ATP, not the proton motive force, appears to be required for NR uptake. Thus, the driving force for NR uptake via PnuC is NR phosphorylation by NadR. A concerted group translocation mechanism can be considered whereby NadR facilitates the dissociation of NR from PnuC by phosphorylating it to NMN, thus preventing efflux of NR.
Sources: en.wikipedia.org
tight junction Also occluding junction or zonula occludens. A type of specialized intercellular junction characterized by very close contact between the plasma membranes of adjacent cells, which are held together by large multiprotein complexes that completely or nearly completely occlude the passage of water and solutes through the intercellular space between cells. Tight junctions occur in many vertebrate tissues, especially between the epithelial and endothelial cells that line the surfaces of most organs and vessels. These cells are completely encircled by tight junctions which create a gasket-like seal that separates each cell's plasma membrane into apical and basolateral domains and prevents the exchange of extracellular materials between them.
Hypoglycemia due to a tumor of the pancreas or elsewhere is usually curable by surgical removal. Most of these tumors are benign. Streptozotocin is a specific beta cell toxin and has been used to treat insulin-producing pancreatic carcinoma. Hyperinsulinism due to diffuse overactivity of beta cells, such as in many of the forms of congenital hyperinsulinism, and more rarely in adults, can often be treated with diazoxide or a somatostatin analog called octreotide. Diazoxide is given by mouth, octreotide by injection or continuous subcutaneous pump infusion. When congenital hyperinsulinism is due to focal defects of the insulin-secretion mechanism, surgical removal of that part of the pancreas may cure the problem. In more severe cases of persistent congenital hyperinsulinism unresponsive to drugs, a near-total pancreatectomy may be needed to prevent continuing hypoglycemia. Even after pancreatectomy, continuous glucose may be needed in the form of gastric infusion of formula or dextrose. High dose glucocorticoid is an older treatment used for presumptive transient hyperinsulinism but incurs side effects with prolonged use.
=== Differential diagnosis === About 99% of HD diagnoses based on the typical symptoms and a family history of the disease are confirmed by genetic testing to have the expanded trinucleotide repeat that causes HD. Most of the remaining are called HD-like (HDL) syndromes. The cause of most HDL diseases is unknown, but those with known causes are due to mutations in the prion protein gene (HDL1), the junctophilin 3 gene (HDL2), a recessively inherited unknown gene (HDL3—only found in two families and poorly understood), and the gene encoding the TATA box-binding protein (SCA17, sometimes called HDL4). Other autosomal dominant diseases that can be misdiagnosed as HD are dentatorubral-pallidoluysian atrophy and neuroferritinopathy. Also, some autosomal recessive disorders resemble sporadic cases of HD. These include chorea acanthocytosis and pantothenate kinase-associated neurodegeneration. One X-linked disorder of this type is McLeod syndrome.
In February 2022, Carrey reprised his role as Ernie "Chip" Douglas, from the 1996 movie The Cable Guy, in a commercial for Verizon, which aired during the Super Bowl. In April 2022, Carrey announced that he was considering retirement, saying: "I have enough. I've done enough. I am enough." He said he would return to acting if "angels bring some sort of script that's written in gold ink that says to me that it's going to be really important for people to see". In February 2024, it was announced that Carrey would reprise his role as Dr. Ivo Robotnik in Sonic the Hedgehog 3. A copy of the script for Sonic the Hedgehog 3 was delivered to Carrey written in 24-carat ink in reference to his previous comments. Carrey also plays Ivo Robotnik's grandfather, Gerald Robotnik. Carrey reportedly told an Associated Press reporter that he agreed to return to the Sonic universe because "I need the money, frankly." He later clarified in interviews in December 2024 that he planned to "power rest" rather than retire, while also stating that he was open to continuing his role in the Sonic film series. In March 2026, Carrey was announced to return as Dr. Ivo Robotnik in Sonic the Hedgehog 4 (2027). In August 2026, Carrey was announced to star in the upcoming live-action film The Jetsons, but his role is yet to be confirmed.
== Toxicities == Nitrofurazone is suspected to be a human carcinogen and is included in California's list of toxic chemicals as defined by Proposition 65. Studies demonstrate that nitrofurazone induces mammary tumors (fibroadenoma and adenocarcinoma) in rats and ovarian tumors in mice. In addition, animal studies demonstrated an increased incidence in convulsive seizures, ovarian atrophy, testicular degeneration, and degeneration of articular cartilage. Proper personal protective equipment should be utilized when handling nitrofurazone.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.